)
Edge14 Aug 2026
Deutsche Qualität: The Story of Birkenstock
From an 18th-century German shoemaker to a global footwear brand, how Birkenstock turned an orthopedic insole into the world's most popular sandal.
Neurogene
Neurogene (NGNE) investor relations material
Neurogene Corporate presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate presentation summary11 Aug, 2026
Mission and approach
Focus on developing life-changing genetic medicines for severe neurological diseases.
Utilizes a biology-first design and precision delivery for maximum drug distribution.
EXACT platform enables precise transgene expression tailored to patient needs.
NGN-401 program highlights
NGN-401 is advancing as a potential one-time, transformative gene therapy for Rett syndrome.
Demonstrated durable, multidomain improvements across all disease severities.
Received multiple FDA designations, including Breakthrough Therapy and RMAT.
Embolden registrational trial completed dosing (N=25), exceeding targets due to high demand.
Topline data from Embolden expected in 2H 2027; BLA-enabling PPQ runs to finish by end of 2026.
Unmet need and market opportunity
Rett syndrome has no approved disease-modifying therapies; current care is lifelong and symptom-focused.
Estimated 15,000–20,000 patients in US, EU, and UK, with ~6,000 diagnosed in the US.
Patient population spans all ages, creating broad adoption potential for transformative therapies.
NGN-401 targets the root genetic cause, aiming to restart developmental progression.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Neurogene
- NGN-401 showed robust efficacy and safety, with cash runway into Q1 2029.NGNE
Q2 2026 - NGN-401's pivotal study nears completion, with 12-month data and US commercialization on track for 2026.NGNEGuggenheim Securities Emerging Outlook: Biotech Summit 2026
- NGN-401 gene therapy enabled rapid, durable, multidomain gains with strong safety in Rett syndrome.NGNEStudy result
- All proposals passed, directors elected, and no shareholder questions or proposals submitted.NGNEAGM 2026
- NGN-401 shows durable, multidomain benefits in Rett syndrome, with pivotal trial and launch prep underway.NGNECorporate presentation
- NGN-401 Embolden trial dosing nears completion; strong cash runway and interim data expected mid-2026.NGNEQ1 2026
- NGN-401 shows sustained, multi-domain gains in Rett syndrome with high responder rates and robust safety.NGNETD Cowen 46th Annual Health Care Conference
- Board recommends approval of all proposals, with detailed governance and compensation disclosures.NGNEProxy filing
- Key votes include director elections, executive pay, auditor ratification, and say-on-pay frequency.NGNEProxy filing
Next Neurogene earnings date
Q3 202613 Nov, 2026
Neurogene
Next Neurogene earnings date
Q3 202613 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage